Healthcare Industry News: proton
News Release - October 30, 2007
Accuray Enters Partnership with Still River SystemsAccuray to Provide Robotic Patient Positioning System for Lower Cost proton Therapy Solution
SUNNYVALE, Calif., Oct. 30 (HSMN NewsFeed) -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that the company has entered into a partnership with Still River Systems, developer of high quality, cost-effective proton beam radiotherapy solutions, and will provide them with a robotic patient positioning system.
Accuray will supply a version of its RoboCouch® Robotic Patient Positioning System, which intelligently positions patients with 6 degrees of freedom for treatment, enabling clinicians to automatically re-position the patient from the control room. The patient positioning system will be used with Still River Systems' Monarch 250(TM) PBRT System, a practical, cost- efficient, single-room proton beam radiotherapy (PBRT) system scaled for use at most cancer centers.
"We are pleased that Still River Systems recognizes Accuray's prominent position in the field of medical robotics and has chosen us to develop their patient positioning system," said Chris Raanes, senior vice president and chief operating officer of Accuray Incorporated. "Accuray's technologies are precise and will allow the Monarch 250 System to provide optimal patient positioning accuracy and comfort."
"As it is well recognized that precise positioning is required to gain the advantages of proton therapy, we are excited to work with Accuray to bring new standards of excellence to positioning patients for these treatments," said Marc Buntaine, CEO of Still River Systems. "With our Monarch 250 System including a custom version of the RoboCouch, physicians will be able to quickly and precisely position patients in correct translation and rotational alignment for each proton treatment fraction."
Accuray Incorporated (Nasdaq: ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 35,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
About Still River Systems
Still River Systems, Inc., a company based in Littleton, Massachusetts, is developing the Monarch250 System, a medical device for the treatment of cancer patients using proton beam radiotherapy (PBRT). The Monarch250 PBRT System is not FDA cleared.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release regarding procedure growth and market acceptance, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward- looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products; need for additional long-term clinical data; the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the fiscal year ended June 30, 2007 and may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward- looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Accuray and China Isotope and Radiation Corporation Enter Joint Venture Contract to Manufacture and Sell Radiation Oncology Systems in China